In the print version of the article listed above, there is an inconsistency in Table 1 on page 8. The weights given in the row summarizing changes in body weight should have been provided in kilograms instead of pounds, given that all weight data discussed in the article was expressed as kilograms. The corrected table row appears below:

TABLE 1.

Summary of Efficacy and Safety of Canagliflozin as Add-On to Metformin, Metformin Plus Sulfonylurea, and Insulin in Patients With Type 2 Diabetes Over 52 Weeks (3,30–33,50,53)

 Canagliflozin as: 
 Add-on to MET Add-on to MET + SU Add-on to insulin 
Changes in key efficacy parameters 
Body weight (kg) GLIM PBO PBO 
  Baseline: 86.6  Baseline: 90.8  Baseline: 97.7 
  Change: +1.0% (+0.7)  Change: –0.9% (–1.0)  Change: +0.1% (+0.1) 
 CANA 100 mg CANA 100 mg CANA 100 mg 
  Baseline: 86.8  Baseline: 93.5  Baseline: 96.9 
  Change: –4.2% (–3.7)  Change: –2.2% (–2.0)  Change: –2.4% (–2.3) 
 CANA 300 mg CANA 300 mg CANA 300 mg 
  Baseline: 86.6  Baseline: 93.5  Baseline: 96.7 
  Change: –4.7% (–4.0)  Change: –3.2% (–3.1)  Change: –3.1% (–3.0) 
 SITA SITA  
  Baseline: 87.6  Baseline: 89.6  
  Change: –1.3% (–1.2)  Change: +0.3% (+0.1)  
 CANA 100 mg CANA 300 mg  
  Baseline: 88.7  Baseline: 87.6  
  Change: –3.8% (–3.3)  Change: –2.5% (–2.3)  
 CANA 300 mg   
  Baseline: 85.4   
  Change: –4.2% (–3.7)   
 Canagliflozin as: 
 Add-on to MET Add-on to MET + SU Add-on to insulin 
Changes in key efficacy parameters 
Body weight (kg) GLIM PBO PBO 
  Baseline: 86.6  Baseline: 90.8  Baseline: 97.7 
  Change: +1.0% (+0.7)  Change: –0.9% (–1.0)  Change: +0.1% (+0.1) 
 CANA 100 mg CANA 100 mg CANA 100 mg 
  Baseline: 86.8  Baseline: 93.5  Baseline: 96.9 
  Change: –4.2% (–3.7)  Change: –2.2% (–2.0)  Change: –2.4% (–2.3) 
 CANA 300 mg CANA 300 mg CANA 300 mg 
  Baseline: 86.6  Baseline: 93.5  Baseline: 96.7 
  Change: –4.7% (–4.0)  Change: –3.2% (–3.1)  Change: –3.1% (–3.0) 
 SITA SITA  
  Baseline: 87.6  Baseline: 89.6  
  Change: –1.3% (–1.2)  Change: +0.3% (+0.1)  
 CANA 100 mg CANA 300 mg  
  Baseline: 88.7  Baseline: 87.6  
  Change: –3.8% (–3.3)  Change: –2.5% (–2.3)  
 CANA 300 mg   
  Baseline: 85.4   
  Change: –4.2% (–3.7)   

CANA, canagliflozin; GLIM, glimepiride; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea.

The online version reflects these changes.